Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist has recently been approved by FDA for type 2 diabetes in adults as a single dose weekly. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity. Tirzepatide is also under evaluation for treatment of non-alcoholic steatohepatitis, heart failure and obstructive sleep apnea.
Keywords
GIP Agonist, GLP–1 Agonist, Incretin, Obesity, Type 2 Diabetes Mellitus.
User
Font Size
Information